Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of IV ferric carboxymaltose (Ferinject) on exercise tolerance in HFpEF with iron deficiency
2015-005757-12Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ferric carboxymaltose in heart failure with preserved ejection fraction (HFpEF) and iron deficiency anemia (IDA), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Primary efficacy endpoint. Started May 2017; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2015-005757-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005757-12.